Appendix B: GENEQOL consortium participants per December 2009
Amy P. Abernethy, Duke Cancer Care Research Program, Duke University Medical Center, Durham, NC, US; Frank Baas, Laboratory of Neurogenetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Andrea M. Barsevick, Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, US; Meike Bartels, Department of Biological Psychology, VU University, Amsterdam, the Netherlands; Dorret I. Boomsma, Department of Biological Psychology, VU University, Amsterdam, the Netherlands; Andrew Bottomley, Quality of Life Department, EORTC Data Center, Brussels, Belgium; Michael Brundage, Department of Oncology, Queen’s University Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada; Cynthia Chauhan, Cancer Advocacy, Wichita, KS, US; David Cella, Department of Medical Social Sciences, Feinberg School of Medicine, Chicago, IL, US; Charles S. Cleeland, Department of Symptom Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, US; Corneel Coens, Quality of Life Department, EORTC Data Center, Brussels, Belgium; Amylou C. Dueck, Section of Biostatistics, Mayo Clinic, Scottsdale, AZ, US; Marlene H. Frost, Women’s Cancer Program, Mayo Clinic, Rochester, MN, US; Per Hall, Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden; Michele Y. Halyard, Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, US; Pål Klepstad, Department of Intensive Care Medicine, St Olavs University Hospital, Norwegian University of Technology and Science, Trondheim, Norway; Nicholas G. Martin, Queensland Institute of Medical Research, Brisbane, Australia; Christine Miaskowski, School of Nursing, University of California, San Francisco, CA, US; Miriam Mosing, Queensland Institute of Medical Research, Brisbane, Australia; Benjamin Movsas, Department of Radiation Oncology, Henry Ford Health System, Detroit, MI, US; Joao R. Oliveira, Department of Neuropsychiatry, Federal University of Pernambuco, Recife—Pernambuco, Brazil; Juan Ordoñana, Department of Human Anatomy and Psychobiology, University of Murcia, Murcia, Spain; Donald L. Patrick, Department of Health Services, University of Washington, Seattle, WA, US; Nancy L. Pedersen, Department of Medical Epidemiology and Biostatistics, Karolinska; Institute, Stockholm, Sweden; Hein Raat, Preventive Youth Health Care, Erasmus Medical Center, Rotterdam, the Netherlands; Bryce Reeve, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, US; Mary E. Ropka, Cancer Prevention and Control Program, Fox Chase Cancer Center, Cheltenham, PA, US; Quiling Shi, Department of Symptom Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, US; Gen Shinozaki, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, US; Jasvinder A. Singh, Minneapolis Veterans Affairs Medical Center and University of Minnesota, Minneapolis, MN and Mayo Clinic College of Medicine, Rochester, MN, US; Jeff A. Sloan, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, US; Mirjam A. G. Sprangers, Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Dick Swaab, The Netherlands Institutes for Neuroscience, Amsterdam, the Netherlands; Cornelis J. F. Van Noorden, Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Ruut Veenhoven, Faculty of Social Sciences, Erasmus University Rotterdam, Rotterdam, The Netherlands; Gert Wagner, Berlin University of Technology, Max Planck Research School LIFE, Berlin, Germany; Ping Yang, Department of Genetic Epidemiology, Mayo Clinic, Rochester, MN, US; Ailko H. Zwinderman, Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.